Back to Search
BRANIMIR SIKIC, MD
MD
Hematology & Oncology Physician
NPI: 1376679548Individual
Specialties, Licenses & Credentials
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
G41273(CA)
Research & Publications (20)
Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors.
PMID 19633048·Ann Oncol·2010
3-trial
A network model of a cooperative genetic landscape in brain tumors.
PMID 19602686·JAMA·2009
4-observational
A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia.
PMID 19108889·Leuk Res·2009
3-trial
Monosomy of chromosome 10 associated with dysregulation of epidermal growth factor signaling in glioblastomas.
PMID 19602687·JAMA·2009
8-other
Leukemic blast and natural killer cell P-glycoprotein function and inhibition in a clinical trial of zosuquidar infusion in acute myeloid leukemia.
PMID 18976810·Leuk Res·2009
3-trial
A phase II study of gefitinib, 5-fluorouracil, leucovorin, and oxaliplatin in previously untreated patients with metastatic colorectal cancer.
PMID 18981005·Clin Cancer Res·2008
3-trial
Analysis of phase II studies on targeted agents and subsequent phase III trials: what are the predictors for success?
PMID 18285603·J Clin Oncol·2008
4-observational
Differential gene expression patterns and interaction networks in BCR-ABL-positive and -negative adult acute lymphoblastic leukemias.
PMID 17312329·J Clin Oncol·2007
8-other
Integrated high-resolution genome-wide analysis of gene dosage and gene expression in human brain tumors.
PMID 17634618·Methods Mol Biol·2007
6-review
Low or absent SPARC expression in acute myeloid leukemia with MLL rearrangements is associated with sensitivity to growth inhibition by exogenous SPARC protein.
PMID 16424866·Leukemia·2006
8-other
Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies.
PMID 16683204·Invest New Drugs·2006
3-trial
Multidrug resistance and stem cells in acute myeloid leukemia.
PMID 16740740·Clin Cancer Res·2006
6-review
Regional activation of chromosomal arm 7q with and without gene amplification in taxane-selected human ovarian cancer cell lines.
PMID 16382445·Genes Chromosomes Cancer·2006
4-observational
Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappaB-mediated resistance to O6-alkylating agents in human glioblastomas.
PMID 16365179·J Clin Oncol·2006
8-other
A pilot phase II trial of valspodar modulation of multidrug resistance to paclitaxel in the treatment of metastatic carcinoma of the breast (E1195): a trial of the Eastern Cooperative Oncology Group.
PMID 17118777·Cancer Invest·2006
3-trial
Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421.
PMID 16254147·Blood·2006
4-observational
Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas.
PMID 16204036·Cancer Res·2005
8-other
Genetic and epigenetic modeling of the origins of multidrug-resistant cells in a human sarcoma cell line.
PMID 16230402·Cancer Res·2005
8-other
Gene expression profiling differentiates germ cell tumors from other cancers and defines subtype-specific signatures.
PMID 16306258·Proc Natl Acad Sci U S A·2005
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 300 PASTEUR DR
STANFORD, CA 94305 - Phone
- (650) 723-4000
Quick Facts
- NPI
- 1376679548
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile